HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Formycon’s US Eylea Biosimilar Is Third In Six Weeks – But Timing Still Uncertain

A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.

Approvals Biosimilars

What’s Next? Five Things To Look Out For In July

Generics Bulletin previews the most noteworthy and anticipated events for July 2024.

Biosimilars Generic Drugs

Apotex Is Latest To Accuse Amarin Of ‘Freezing Out’ Vascepa Competition

Apotex is the latest generics manufacturer that feels Amarin has engineered a “systematic effort to ensure that no other company could manufacture the generic version of its product,” Vascepa, by locking up API supply, with the Canadian firm taking legal action in a bid to bring the originator’s alleged conduct to a halt.

Litigation Legal Issues

Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal

Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.

Deals M & A

‘Totality, Not Piecemeal’: US Federal Circuit Revives Hikma Vascepa Skinny-Label Suit

Reading Hikma’s press releases and other public documents made it “at least plausible” that a physician would look to prescribe Hikma’s generic Vascepa product for any of its indications, including the highly-valued, patent-protected cardiovascular indication, the US Federal Circuit has decided, reopening a lawsuit against the generics firm.

Legal Issues Litigation

AAM Knocked Back In Illinois Price-Gouging Lawsuit

Off-patent industry association the US Association for Accessible Medicines will have to reevaluate after a US district court in Illinois found that it had no standing to secure injunctive relief against a state price-control bill.

Generic Drugs Legal Issues
See All
UsernamePublicRestriction

Register